Recent Chart Audit Reveals Switching Rheumatoid Arthritis Patients to Roche/Genentech's RoActemra (Actemra) is Significantly More Common in the EU5 than it is in the US
Advertisement
EU5 adoption of Pfizer's Xeljanz and Eli Lilly's Olumiant has been largely limited to rheumatologists practicing in Germany, according to a recently released independent report by Spherix Global Insights